Active Filter(s):
Details:
Under the agreement, OncoVent agreed to grant exclusive rights to OEP, which will be responsible for the commercialization of MAb-B43.13 (oregovomab), an immunotherapy drug candidate, in Taiwan, including related regulatory applications and necessary clinical trials.
Lead Product(s): Oregovomab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: MAb-B43.13
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Orient EuroPharma
Deal Size: $11.2 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 28, 2023